EUVIMEDEUVIMED entdecken
Crossref

Sirolimus experience in adult patients with vascular malformations

Arif Akyildiz, Rashad Ismayilov iD, Deniz Can Guven, Hasan Cagri Yildirim, Omer Denizhan Tatar iD, Fatih Kus, Elvin Chalabiyev, Fatma Alev Turker, Omer Dizdar, Suayib Yalcin, Halil Ibrahim Gullu

Vascular · 2025

DOI: 10.1177/17085381241241853 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Vascular, 2025. Verfasst von Arif Akyildiz und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Hacettepe University Medical School, Ankara, Turkey. Hauptthemen laut MEDLINE: Sirolimus, Vascular Malformations, MTOR Inhibitors. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 20 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

Sirolimus, a mammalian target of rapamycin inhibitor, inhibits cell growth and proliferation by controlling ribosome biogenesis and protein synthesis in vascular anomalies and cancers. However, most sirolimus studies on vascular anomalies were conducted in the pediatric population, with limited data in adults. In this study, we assessed the effectiveness and safety of sirolimus in adult patients with vascular malformation, a subtype of vascular anomaly.

Methods

We conducted a retrospective analysis of adult vascular malformation patients aged over 16, treated at Hacettepe University Cancer Institute from January 2013 to September 2022. Patient demographics and clinical characteristics were recorded. The primary outcome was the efficacy of sirolimus evaluated by response and disease control rates. The disease control rate was defined as the cumulative percentage of complete or partial responses, along with stable disease. The secondary endpoint was toxicity and safety.

Results

38 patients with a median age of 21 (IQR: 18–33) were recruited. Prior to sirolimus treatment, 57.9% of patients had undergone other therapeutic interventions, predominantly sclerotherapy and surgery. The median follow-up time during sirolimus treatment was 18.5 (IQR: 11.3–74.5) months. The disease control rate was 92.1% (35/38). Head-neck localization was associated with better response rates ( p = .001). Sirolimus was generally well tolerated and grade 1 or 2 oral mucositis ( n = 4) and skin rash ( n = 3) were the most common side effects.

Conclusion

In this study, we found sirolimus was efficacious and well tolerated in adult patients with vascular malformation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SirolimusVascular MalformationsMTOR InhibitorsHumansFemaleMaleAdultRetrospective StudiesTreatment OutcomeYoung AdultAdolescentTime Factors

Stichwörter der Autor:innen

Vascular anomalyadultsmammalian target of rapamycin inhibitorssirolimusvascular malformation

Substanzen

SirolimusMTOR Inhibitors

Autor:innen und Institutionen

  • Department of Medical Oncology, Hacettepe University Medical School, Ankara, Turkey.
  • Department of Internal Medicine, Hacettepe University Medical School, Ankara, Turkey.

ORCID-Profile: Rashad Ismayilov, Omer Denizhan Tatar

Zitieren

APA

Akyildiz, A., Ismayilov, R., Guven, D. C., Yildirim, H. C., Tatar, O. D., Kus, F., Chalabiyev, E., Turker, F. A., Dizdar, O., Yalcin, S., & Gullu, H. I. (2025). Sirolimus experience in adult patients with vascular malformations. Vascular. https://doi.org/10.1177/17085381241241853

Vancouver

Akyildiz A, Ismayilov R, Guven DC, Yildirim HC, Tatar OD, Kus F, et al. Sirolimus experience in adult patients with vascular malformations. Vascular. 2025. doi:10.1177/17085381241241853

BibTeX
@article{Akyildiz2025,
  author = {Akyildiz, Arif and Ismayilov, Rashad and Guven, Deniz Can and Yildirim, Hasan Cagri and Tatar, Omer Denizhan and Kus, Fatih and Chalabiyev, Elvin and Turker, Fatma Alev and Dizdar, Omer and Yalcin, Suayib and Gullu, Halil Ibrahim},
  title = {Sirolimus experience in adult patients with vascular malformations},
  journal = {Vascular},
  year = {2025},
  doi = {10.1177/17085381241241853}
}
Kostenlos starten →